Close Menu
    Drugs

    Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes

    Gerald NgBy
    MCA Thumbnails 2 2 3
    MCA Thumbnails 2 2 3
    Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

    Log In or Register as a healthcare professional to read the full article.

    Share.
    cropped Circle

    Gerald Ng is a previous editor for Medical Channel Asia. Writing has always been his first love and he has more than a decade of journalism experience after falling in love with reading the newspapers daily growing up in Singapore. His works and interviews have appeared in various media publications including Yahoo!, Straits Times and Channel NewsAsia.

    Related Posts

    MCAsia Long Logo white e1725635014416
    Copyright © Medical Channel Asia 2024. All rights reserved.
    The contents on Medical Channel Asia are for general educational purposes only.
    It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
    See additional information.
    Existing Users Click here to login.
    Register with us by filling out the form below.
    Address Fields
    The address information you provide will be used for verifying your identity and personalizing your experience on our platform. We ensure the confidentiality and security of your address details in compliance with our privacy policy.
    Identification
    Your identification details are required for secure account creation and to ensure that your profile is unique and verifiable.